T cell receptor recognizing NY-ESO-1 antigen short peptide
A cell receptor, cell technology, applied in the field of TCR, can solve problems such as normal cell damage
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0129] Example 1 Cloning NY-ESO-1 Antigen Short Peptide-Specific T Cells
[0130]Peripheral blood lymphocytes (PBL) from healthy volunteers with the genotype HLA-A0201 were stimulated with the synthetic short peptide SLLMWITQC (Beijing Saibaisheng Gene Technology Co., Ltd.). The pHLA haploid was prepared by annealing SLLMWITQC short peptide with biotin-labeled HLA-A*0201. These haploids were combined with PE-labeled streptavidin (BD Company) to form PE-labeled tetramers, and the tetramers and anti-CD8-APC double-positive cells were sorted. Sorted cells were expanded and subjected to secondary sorting as described above, followed by monoclonalization by limiting dilution. Monoclonal cells were stained with tetramers, and the double-positive clones screened were as follows: image 3 shown.
Embodiment 2
[0131] Example 2 Obtaining the TCR gene and carrier construction of NY-ESO-1 antigen short peptide-specific T cell clone
[0132] with Quick-RNA TM MiniPrep (ZYMO research) extracted the total RNA of the short antigen peptide SLLMWITQC-specific and HLA-A0201-restricted T cell clones screened in Example 1. The cDNA was synthesized using clontech's SMART RACE cDNA amplification kit, and the primers used were designed at the C-terminal conserved region of the human TCR gene. The sequence was cloned into T vector (TAKARA) for sequencing. It should be noted that this sequence is complementary and does not contain introns. After sequencing, the sequence structures of the TCR α chain and β chain expressed by the double-positive clone are shown in Figure 1 and Figure 2, respectively. Figure 1a , Figure 1b , Figure 1c , Figure 1d , Figure 1e with Figure 1f They are the amino acid sequence of TCRα chain variable domain, the nucleotide sequence of TCRα chain variable domain,...
Embodiment 3
[0142] Example 3 Expression, refolding and purification of NY-ESO-1 antigen short peptide-specific soluble TCR
[0143] In order to obtain a soluble TCR molecule, the α and β chains of the TCR molecule of the present invention may only include their variable domains and part of the constant domains respectively, and a cysteine residue is introduced into the constant domains of the α and β chains respectively To form an artificial interchain disulfide bond, the positions of the introduced cysteine residues are Thr48 of TRAC*01 exon 1 and Ser57 of TRBC2*01 exon 1; the amino acid sequence and nucleotides of the α chain sequence as Figure 4a with Figure 4b As shown, the amino acid sequence and nucleotide sequence of its β chain are as follows Figure 5a with Figure 5b The introduced cysteine residues are indicated in bold letters. The target gene sequences of the above TCRα and β chains were synthesized and inserted into the expression vector pET28a+ (Novagene ), the...
PUM
Login to view more Abstract
Description
Claims
Application Information
Login to view more - R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap